
Thursday, April 04, 2019 1:24:03 PM
From their latest 10K. -
We have ownership positions in Eton, Surface, Melt, and Mayfield and hold royalty interests in certain of their drug candidates. These companies are pursuing market approval for their drug candidates under the FDCA, including under the abbreviated pathway described in Section 505(b)(2) which permits the submission of a new drug application (NDA) where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. In 2018, we formed our Radley and Mayfield subsidiaries We intend to pursue our business strategies though subsidiaries and royalty interests that will focus on the development and FDA approval of certain proprietary drug formulations that we currently own, will in-license/acquire and/or otherwise develop.
saving nickels saving dimes
working till the sun don't shine
looking forward to happier times
1963, Roy Orbison - On Blue Bayou
Recent HROW News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 08:01:38 PM
- Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. • Business Wire • 09/29/2023 12:00:00 PM
- Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation • Business Wire • 09/26/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2023 10:39:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:30:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:26:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:05:41 PM
- Harrow Announces Second Quarter 2023 Financial Results • Business Wire • 08/09/2023 08:01:00 PM
- Harrow Launches VIGAMOX® in the U.S. • Business Wire • 07/31/2023 11:00:00 AM
- Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 • Business Wire • 07/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/20/2023 11:46:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/20/2023 11:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/19/2023 09:19:37 PM
- Harrow Prices $60 Million Public Offering of Common Stock • Business Wire • 07/19/2023 11:00:00 AM
- Harrow erwirbt US-amerikanische und kanadische Vermarktungsrechte für VEVYE® (Cyclosporin-Augenlösung) 0,1 % von Novaliq • Business Wire • 07/19/2023 02:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/18/2023 09:03:23 PM
- Harrow Acquires Santen’s Branded Ophthalmic Portfolio • Business Wire • 07/18/2023 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 08:59:25 PM
- Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance • Business Wire • 07/18/2023 08:05:00 PM
- Harrow Announces Proposed Public Offering of Common Stock • Business Wire • 07/18/2023 08:04:00 PM
- Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq • Business Wire • 07/18/2023 08:01:00 PM
- Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 • Business Wire • 05/17/2023 12:00:00 PM
- Harrow Announces First Quarter 2023 Financial Results • Business Wire • 05/11/2023 08:01:00 PM
- Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting • Business Wire • 05/04/2023 12:00:00 PM
FEATURED Cannabix's MSBS Marijuana Breathalyzer Technology Advances Quantification of THC in Breath • Oct 3, 2023 8:50 AM
Good Gaming, Inc. Announces Galactic Acres™ as Its First Mobile Game Integrated with Web3 Technology • GMER • Oct 3, 2023 8:30 AM
HealthLynked Announces Patent Filing for ARI: A Revolutionary AI-Powered Healthcare Interface • HLYK • Oct 3, 2023 8:00 AM
Nate's Food Co Successfully Completes Cancellation of 1 Billion Common Shares, Paving the Way for a Bright Future • NHMD • Oct 3, 2023 8:00 AM
Branded Legacy Expands Facility to 11,000 Sqft, Extends LOI for Acquisition of The Alcannabist LLC • BLEG • Oct 3, 2023 8:00 AM
Image Protect Announces Memorandum of Understanding for Pending New Business Acquisition • IMTL • Oct 2, 2023 8:14 AM